+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Germany Diagnostic Biomarker Market 2019-2025

  • PDF Icon


  • January 2020
  • Region: Germany
  • Orion Market Research Private Limited
  • ID: 4991533
UP TO OFF until Dec 31st 2022
Germany Diagnostic Biomarker Market Size, Share & Trends Analysis Report by Diagnostic Technique (ELISA, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, Particle-Enhanced Turbidimetric Immunoassay, and Others), By Application (Oncology, Cardiology, Neurology, Nephrology, and Others), and Forecast 2019-2025.

German diagnostic biomarker market is estimated to grow significantly at a CAGR of over 12% during the forecast period. It is due to the increasing geriatric population, the presence of highly specialized urologists for cancer treatment and bit low-cost treatment as compared to UK, which is attracting medical tourism in the country. In addition, Germany has a well-developed healthcare system and favorable government policies which are driving the market in the region.

The German diagnostic biomarker market is segmented on the basis of diagnostic technique and application. On the basis of the diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. Further, on the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A large number of researches are going on finding a diagnostic biomarker for various types of cancer so that early detection can be done.

Some of the major players in the Germany diagnostic biomarker market include Abbott Laboratories, Inc., F. Hoffmann-La Roche Ltd., Evotec AG, Becton Dickinson and Co., SphingoTec GmbH, InfanDx AG, Novartis AG, and others. These companies are adopting various strategies such as partnership and collaboration and product launch, in order to sustain in the competitive market. In addition, the players are involved in the R&D activities and filing patents for the same. For instance, in January 2020, InfanDx AG has been granted the US Patent 141013 US, titled „Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy”. The US Patent and Trademark Office approved the comprehensive patent, which covers the diagnosis of neonatal encephalopathy using biomarkers, at the end of December 2019. This is the second US patent for the HypoxE-test, following the patent for the diagnosis of perinatal asphyxia. In the EU, InfanDx had already been awarded patent protection for both indications.

Research Methodology

The market study of the German diagnostic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Germany Diagnostic Biomarker Market Research and Analysis by Diagnostic Technique
2. Germany Diagnostic Biomarker Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the Germany Diagnostic Biomarker Market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Germany Diagnostic Biomarker Market.
  • Insights about market determinants which are stimulating the Germany Diagnostic Biomarker Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Germany Diagnostic Biomarker Market by Diagnostic Technique
5.1.1. ELISA
5.1.2. Colorimetric Assay
5.1.3. Liquid Chromatography-Mass Spectrometry
5.1.4. Particle-Enhanced Turbidimetric Immunoassay
5.1.5. Others
5.2. Germany Diagnostic Biomarker Market by Application
5.2.1. Oncology
5.2.2. Cardiology
5.2.3. Neurology
5.2.4. Nephrology
5.2.5. Others
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.2. Abcodia Ltd.
6.3. Agilent Technologies, Inc.
6.4. Avacta Group Plc
6.5. Bayer AG
6.6. Becton, Dickson, and Co.
6.7. BioMérieux S.A.
6.8. Bio-Rad Laboratories, Inc.
6.9. Eurofins Scientific SE
6.10. Evotec AG
6.11. F-Hoffman-La Roche Ltd.
6.12. InfanDx AG
6.13. Novartis AG
6.14. Pfizer, Inc.
6.15. SphingoTec GmbH
6.16. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Abcodia Ltd.
  • Agilent Technologies, Inc.
  • Avacta Group Plc
  • Bayer AG
  • Becton, Dickson, and Co.
  • BioMérieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific SE
  • Evotec AG
  • F-Hoffman-La Roche Ltd.
  • InfanDx AG
  • Novartis AG
  • Pfizer, Inc.
  • SphingoTec GmbH
  • Thermo Fisher Scientific Inc.